Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...

DENVER—Use of everolimus (EVR) rather than mycophenolic acid (MPA) in renal transplant recipients may significant decrease the risk for cytomegalovirus events, according to a study. “These findings ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Maribavir is an effective and well-tolerated option for cytomegalovirus infection and disease among hematopoietic cell ...

Federal data indicate that over half the US population aged 6-46 years is infected with cytomegalovirus (CMV), typically spread through bodily fluids. Most people have mild or no negative effects from ...